A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms ABC-X; ABC-X Study
- 11 Sep 2019 Status changed from not yet recruiting to recruiting.
- 22 Jul 2019 Planned primary completion date changed from 1 Jul 2022 to 1 Aug 2022.
- 22 Jul 2019 Planned initiation date changed from 1 Jul 2019 to 1 Aug 2019.